In Vitro Combination Effect of Topical and Oral Anti-Onychomycosis Drugs on Trichophyton rubrum and Trichophyton interdigitale

To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for Trichophyton rubrum and Trichophyton interdigitale (8 each, with a total of 16 strains) were determined using the microdilution checkerboard technique based on the Clinical and Laboratory Standard Institute guidelines. No antagonism was observed between the topical and oral drugs against all the tested strains. Efinaconazole with terbinafine exerted a synergistic effect on 43.8% of the strains tested (7/16 strains) and efinaconazole with itraconazole on 12.5% (2/16 strains). Conversely, luliconazole showed no synergistic effect with terbinafine but was synergistically effective with itraconazole against 31.3% of the strains (5/16 strains). Tavaborole showed no synergistic effect with terbinafine and was synergistically effective with itraconazole against 18.8% of the strains (3/16 strains). The results suggest that a combination of topical and oral drugs could be a potential clinical option for onychomycosis treatment, and overall, the efinaconazole and oral drug combination would be the most advantageous among the tested combinations.

[1]  E. Dannaoui,et al.  Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations , 2021, Journal of fungi.

[2]  Evy Ervianti,et al.  COMBINATION ANTIFUNGAL THERAPY FOR ONYCHOMYCOSIS , 2018 .

[3]  S. Poojary Topical antifungals: A review and their role in current management of dermatophytoses , 2017 .

[4]  Yoshiki Matsuda,et al.  Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis , 2016, PloS one.

[5]  N. Bhatia,et al.  The Dermatologist’s Approach to Onychomycosis , 2015, Journal of fungi.

[6]  A. Kaszuba,et al.  Amorolfine vs. ciclopirox – lacquers for the treatment of onychomycosis , 2015, Postepy dermatologii i alergologii.

[7]  J. Lear,et al.  British Association of Dermatologists' guidelines for the management of onychomycosis 2014 , 2014, The British journal of dermatology.

[8]  B. Elewski,et al.  Tavaborole for the treatment of onychomycosis , 2014, Expert opinion on pharmacotherapy.

[9]  K. Makimura,et al.  In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes , 2014, Microbiology and immunology.

[10]  Bharti Bharti,et al.  A study to compare efficacy of various oral antifungals (Fluconazole, Terbinafine, Itraconazole) in treatment of Onychomycosis , 2014 .

[11]  Aditya K. Gupta,et al.  Improved efficacy in onychomycosis therapy. , 2013, Clinics in dermatology.

[12]  S. Botton,et al.  Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. , 2013, Revista iberoamericana de micologia.

[13]  Y. Nishiyama,et al.  Mechanism of Action of Efinaconazole, a Novel Triazole Antifungal Agent , 2013, Antimicrobial Agents and Chemotherapy.

[14]  G. Petrikkos,et al.  In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs. , 2012, The Journal of antimicrobial chemotherapy.

[15]  Aditya K. Gupta,et al.  New therapeutic options for onychomycosis , 2012, Expert opinion on pharmacotherapy.

[16]  H. Korting,et al.  Management of Onychomycoses , 1999, Drugs.

[17]  K. Iozumi,et al.  Epidemiological survey of foot diseases in Japan: Results of 30 000 foot checks by dermatologists , 2010, The Journal of dermatology.

[18]  Yong-qiang Zhang,et al.  Mechanism of the Synergistic Effect of Amiodarone and Fluconazole in Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.

[19]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[20]  T. Peláez,et al.  Synergistic Effect of Posaconazole and Caspofungin against Clinical Zygomycetes , 2007, Antimicrobial Agents and Chemotherapy.

[21]  D. A. Santos,et al.  In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. , 2006, Medical mycology.

[22]  S. Avner,et al.  Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis , 2005, The Journal of dermatological treatment.

[23]  R Baran,et al.  Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  H. Maibach,et al.  Progress on New Therapeuties for Fungal Nail Infections , 2005 .

[25]  H. Ashbee,et al.  Testing of antifungal combinations against yeasts and dermatophytes , 2004, The Journal of dermatological treatment.

[26]  B. Sigurgeirsson,et al.  Combination therapy for onychomycosis. , 2003, The British journal of dermatology.

[27]  C B Moore,et al.  In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. , 2002, The Journal of antimicrobial chemotherapy.

[28]  M. Rinaldi,et al.  In Vitro Activities of Terbinafine in Combination with Fluconazole, Itraconazole, Voriconazole, and Posaconazole against Clinical Isolates of Candida glabrata with Decreased Susceptibility to Azoles , 2002, Journal of Clinical Microbiology.

[29]  C. Lynde,et al.  Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. , 2001, Journal of the American Academy of Dermatology.

[30]  F. Müller,et al.  Synergism of Voriconazole and Terbinafine against Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis , 2001, Antimicrobial Agents and Chemotherapy.

[31]  N S Ryder,et al.  Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. , 2001, Medical mycology.

[32]  A. Coquerel,et al.  Pharmacokinetics of Antifungal Agents in Onychomycoses , 2001, Clinical pharmacokinetics.

[33]  R. Summerbell,et al.  Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. , 2000, Journal of the American Academy of Dermatology.

[34]  B. Elewski,et al.  Onychomycosis: Pathogenesis, Diagnosis, and Management , 1998, Clinical Microbiology Reviews.

[35]  L. Hansson Rationale for combination therapy. , 1987, British journal of clinical pharmacology.